Cardiovascular disease (CVD), such as ischemic heart disease (IHD), congestive heart failure (CHF), transient ischemic attacks (TIA), and stroke, is a leading cause of morbidity and mortality in the general population worldwide. According to the World Health Organization, 17.5 million people die each year from CVD, constituting approximately 30% of all deaths worldwide[@b1]. Cardiovascular diseases therefore place a great burden on people, the economy, and society in general. However, cardiovascular disorders are largely preventable. The identification of new cardiovascular risk factors and interventions to modify these factors is of great importance for addressing the current epidemic.

Osteoarthritis (OA) is also a major cause of morbidity and healthcare expenditures and affects approximately 15% of the population[@b2]. By age 65, 80% of the population has radiographic evidence of OA, and 60% are experiencing symptoms of OA[@b3].

Recent epidemiological studies have suggested a potential relationship between OA and CVD, with conflicting results. Whereas Jonsson *et al*. found a linear association between the severity of hand OA and atherosclerosis in the AGES Reykjavik study[@b4], Haugen *et al*. concluded that symptomatic hand OA but not radiographic hand OA was associated with an increased risk of coronary heart disease events using the data from the Framingham Heart Study[@b5]. Moreover, the results from the Rotterdam Study indicated that disability, not OA, predicted cardiovascular disease[@b6]. This topic remains controversial, and the meta-analysis presented here provides a valid and up-to-date summary of the relevant literature. We aimed to determine whether OA patients are at increased risk of CVD. We also evaluated whether this association differs by type of OA or CVD.

Results
=======

Literature search
-----------------

Overall, 3,075 references were initially identified. After the initial screening of titles and abstracts, a total of 3,028 articles were excluded, leaving 47 articles for retrieval. Full text assessment of these articles resulted in 15 eligible articles that met our inclusion criteria[@b4][@b5][@b6][@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18]. The total number of participants included was 358,944, with 80,911 OA patients and 29,213 CVD patients. [Figure 1](#f1){ref-type="fig"} displays the process of selection of studies.

Study characteristics
---------------------

[Table 1](#t1){ref-type="table"} shows the characteristics of the 15 included articles. The articles included in our systematic review were quite heterogeneous. Five were retrospective studies[@b4][@b9][@b12][@b14][@b16], and 10 were prospective studies[@b5][@b6][@b7][@b8][@b10][@b11][@b13][@b15][@b17][@b18]. The studies were conducted in the United States[@b5][@b7][@b10][@b14], Europe[@b4][@b6][@b8][@b9][@b11][@b12][@b18], Canada[@b15][@b16], and Japan[@b17]. Thirteen studies included men and women[@b4][@b5][@b6][@b8][@b9][@b10][@b12][@b13][@b14][@b15][@b16][@b17][@b18], and four reported results separately by sex[@b4][@b8][@b13][@b16]; the other two studies included only women[@b7][@b11].

Features of exposure varied across studies. Although 12 studies ascertained OA by either radiographic results or medical records[@b4][@b5][@b6][@b7][@b8][@b9][@b11][@b12][@b13][@b17][@b18], the other three used questionnaires to confirm OA status[@b10][@b14][@b16]. The studies focused on different sites of OA, including the hand[@b4][@b6][@b8][@b11][@b18], knee[@b6][@b11][@b17][@b18], or hip[@b6][@b7][@b18].

The method of outcome ascertainment varied across articles. Although the majority of articles ascertained CVD by medical records, three articles used questionnaires to ascertain CVD[@b4][@b14][@b16]. Two articles[@b6][@b12] reported an overall risk outcome, 3[@b5][@b14][@b18] reported both an overall risk outcome and separately for different outcomes, 6[@b7][@b8][@b10][@b11][@b13][@b17] reported risk estimate for one specific outcome. The others[@b4][@b9][@b15][@b16] reported risk estimates separately for different outcomes; and in this case, the risk estimate for the most prevalent type of outcome serves as a surrogate for CVD risk estimate in the pooled analysis.

Although the included articles were quite heterogeneous, the inter-reviewer reliability for data extraction was almost perfect (kappa ranged 0.99--1.00). All studies were rated as medium to high quality.

Systematic review of evidence
-----------------------------

Fifteen articles provided 19 risk estimates of the association between OA and CVD risk. Of these 19 estimates, 11 reported that OA was associated with a significantly increased risk of CVD, five that OA was associated with a non-significantly increased CVD risk, and three that OA was associated with a non-significantly decreased CVD risk. No study included in this systematic review reported that OA was associated with a significantly decreased risk of CVD.

For the non-parametric sign test, we considered whether studies reported an increased or decreased risk of CVD associated with OA, regardless of significance level or magnitude of effect. Overall, 16 risk estimates found that OA was associated with an increased risk of CVD, and three found that OA was associated with a decreased risk of CVD. The sign test (P = 0.004) rejected the null hypothesis of equal CVD risk in patients with and without OA.

Meta-analysis
-------------

[Figure 2](#f2){ref-type="fig"} displays the results of the meta-analysis of the 15 articles. A high level of between-study heterogeneity was detected, with *I*^2^ = 85.1%. Overall, the risk of CVD was significantly increased by 24% (RR: 1.24, 95% CI: 1.12 to 1.37, P \< 0.001) in patients with OA compared with the general population. No significant publication bias was observed according to the Egger test (P = 0.659) or funnel plot ([Supplementary Figure S1](#S1){ref-type="supplementary-material"}).

A sensitivity analysis was performed to evaluate the impact of additional study characteristics on the pooled RR. First, we calculated separate estimates by study design and found that the prospective studies (12 estimates) had a pooled RR of 1.30 (95% CI: 1.16 to 1.46, P \< 0.001) and the retrospective studies (seven estimates) had a pooled RR of 1.15 (95% CI: 0.95 to 1.38, P = 0.147).

Second, we excluded studies that ascertained OA or CVD status by questionnaire. The remaining studies had a pooled RR of 1.26 (95% CI: 1.12 to 1.42, P \< 0.001). Finally, we excluded individual study estimates one at a time to examine the influence of each study on the overall RR. We found that the omission of any one study did not appreciably change the pooled RR ([Supplementary Figure S2](#S1){ref-type="supplementary-material"}).

Subgroup analysis and meta-regression analysis
----------------------------------------------

When subgroups were stratified by study design, we found a significant effect of prospective studies (RR: 1.30, 95% CI: 1.16 to 1.46, P \< 0.001) and a non-significant effect of retrospective studies (RR: 1.15, 95% CI: 0.95 to 1.38, P = 0.147). The stratified analysis according to OA site included 3 subgroups, hand (RR: 1.03, 95% CI: 0.85 to 1.25, P = 0.749), knee (RR: 1.30, 95% CI: 1.00 to 1.69, P = 0.047) and hip (RR: 1.23, 95% CI: 1.11 to 1.38, P \< 0.001). When studies were stratified according to confirmation methods for OA, we found a RR of 1.47 (95% CI: 0.91 to 2.39, P = 0.118) for clinical OA and a RR of 1.23 (95% CI: 1.02 to 1.48, P = 0.028) for radiographic OA. When studies were stratified according to different CVD types, we found significant results for the IHD (RR: 1.33, 95% CI: 1.20 to 1.46, P \< 0.001), CHF (RR: 1.40, 95% CI: 1.13 to 1.73, P = 0.002) and cardiovascular death (RR: 1.53, 95% CI: 1.27 to 1.84, P \< 0.001) subgroups, whereas a non-significant result was found for the stroke subgroup (RR: 1.11, 95% CI: 0.96 to 1.29, P = 0.16). Finally, we considered whether subgroup analysis reported a higher or lower CVD risk associated with OA, regardless of significance level. The results indicated that all subgroup estimates found that OA was associated with an increased risk of CVD. The results of the subgroup analyses are summarized in [Table 2](#t2){ref-type="table"}.

The impact of age and follow up time on the pooled result was explored by meta-regression analysis. As illustrated in [Supplementary Figures S3, S4](#S1){ref-type="supplementary-material"} and [S5](#S1){ref-type="supplementary-material"}, there was no significant impact of age and follow up time on the pooled result.

Discussion
==========

This is the most comprehensive systematic review and meta-analysis of published observational studies assessing the relationship between OA and CVD risk. The results of our meta-analysis demonstrate that OA is associated with a significantly increased risk of CVD. Furthermore, this association was robust across sensitivity analyses that accounted for the influence of each individual study.

The underlying mechanisms behind the observed association between OA and CVD risk remain unclear, but several factors may account for this relationship. First, the two diseases have some shared risk factors. Epidemiological studies have provided evidence for an association between OA and most of the traditional cardiovascular risk factors, including hypertension[@b19][@b20], diabetes[@b21], hypercholesterolemia[@b22], and obesity[@b23]. Second, the most commonly prescribed drugs to relieve pain in OA patients are non-steroidal anti-inflammatory drugs (NSAIDs), and NSAIDs have been related to an increased risk of vascular events[@b24]. Third, OA patients are less physically active because of severe pain in the joints compared with the general population, particularly those with knee or hip OA. Physical inactivity is among the leading risk factors for CVD[@b25]. Finally, the most important pathological features of CVD include arterial thickening, stiffness, and atherosclerosis, which contribute to inadequate tissue perforation (ischemia). Ischemia of the bone decreases cartilage nutrition and induces multiple bone infarcts, which are characteristics of advanced OA[@b26][@b27]. This effect of ischemia of the bone is one potential explanation of the interrelationship between OA and CVD.

Potential limitations of this meta-analysis arise from the unavailability of individual participant data from the included studies. For instance, Jonsson *et al*.[@b4] reported that the intake of polyunsaturated fatty acids was significantly more frequent in the OA group than in the control group, which potentially explained the inverse association between OA and cardiovascular events; Nielen *et al*.[@b12] reported that the mean age of OA patients was significantly higher than that of controls, and thus it is likely that the OA patients with the highest risks had already died, resulting in an underrepresentation of the prevalence rate of CVD in OA patients. With more information, we would be able to analyze the associations between different types of OA and certain types of outcomes as well as better control confounding factors. To overcome this limitation, we performed subgroup analyses when possible. As a significant association was observed in most subgroups, the lack of individual participant data was not a serious limitation. The non-significant results observed in several subgroups can be partially ascribed to the 2 articles mentioned above, which did not control confounders well. Our meta-analysis was based on studies that varied in many ways (study design, population sample, adjustment for confounders, and different ascertainment methods for exposure and outcome), which may be considered another limitation. However, we adopted appropriate meta-analytic techniques with random-effect models, which enabled us to account for these differences.

The strengths of this study include the comprehensive and systematic review of the literature. Study selection, data extraction, and quality assessment were performed independently by two authors according to predesigned criteria to minimize bias and transcription errors. We included both prospective and retrospective studies that used large sample sizes, which increased the statistical power to detect potential associations. Compared to the previous meta-analysis on this topic[@b28], we incorporated 3 times more articles (15 versus 5) and approximately 2 times more participants (358,944 versus 177,214) in the statistical analysis. Furthermore, the included studies had generally satisfactory designs, methods, and outcomes, and the study quality was medium to high. Finally, the consistency of the evidence overall supports a real association between OA and CVD risk.

Because OA is a very common health condition, an association between OA and CVD would be important from a public health perspective. In the general population, middle-aged people may consider screening for OA status as well as traditional cardiovascular risk factors to enable early intervention to reduce future CVD events. Patients with OA should pay more attenuation to their CVD risk. Among clinicians, cardiovascular risk must be taken into account when prescribing any non-steroidal anti-inflammatory drug for OA patients.

In conclusion, this meta-analysis provides strong evidence that OA is a significant risk factor for CVD. Given the high prevalence and incidence of OA and CVD in the general population, the observed relationship between OA and CVD has clinical and public health importance.

Methods
=======

Search strategy
---------------

We carried out a meta-analysis of studies that evaluated the association between osteoarthritis and cardiovascular diseases in adults. We followed the quality of reporting of meta-analysis guidelines (the PRISMA statement) for performing and reporting the present meta-analysis ([Supplementary Tables S1](#S1){ref-type="supplementary-material"} and [S2](#S1){ref-type="supplementary-material"})[@b29]. Between March 2016 and May 2016, we searched Medline and EMBASE to retrieve relevant studies. The following search terms were used in different combinations: osteoarthritis, cardiovascular disease, coronary artery disease, coronary heart disease, ischemic heart disease, myocardial infarction, congestive heart failure, transient ischemic attack, and stroke. Further information was identified through a manual search of references from the extracted papers.

Study selection
---------------

The eligibility of studies was assessed through a three-step process. First, two independent reviewers performed an initial screening of all titles and abstracts according to the following criteria: (1) original research articles were included, and other types of articles, including reviews, editors, commentaries and meta-analyses, were excluded; (2) population-based association studies reporting the relationship between OA and CVD risk were included, and articles focused on other exposure or outcomes were excluded. The full texts of all potentially relevant articles were then reviewed, and studies were included if they met the following criteria: (1) predefined diagnosis criteria for both OA and CVDs; (2) reported risk ratio (RR), hazards ratio (HR), or odds ratio (OR) estimates and 95% CIs describing the relationship between OA and risk of CVDs; (3) inclusion of a non-exposed group in prospective studies or a control group in retrospective studies. Finally, discrepancies were resolved by consensus or consultation with a third reviewer.

Data extraction and quality assessment
--------------------------------------

We designed a standardized data collection form to extract information. Two reviewers independently performed the extraction of data. We adopted OR for retrospective studies and HR and RR for prospective studies as a measure of the association. The following characteristics were recorded in the data abstraction form: study name, authors, year of publication, residential region, type of study, source of the study population, OA and CVD definition, sample size, and adjusted confounding factors.

After the data extraction procedure, the two forms from the two reviewers were compared in a point-by-point manner, and the degree of agreement between the reviewers was assessed using kappa statistics. Any discrepancies were resolved by consensus with a third investigator while referring to the original article.

Finally, we assessed study quality according to the Newcastle--Ottawa quality assessment scale, which was recommended by the Cochrane guidelines. Details of the scoring system and the quality score of each study are listed in [Supplementary Tables S3](#S1){ref-type="supplementary-material"} and [S4](#S1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

For each study, we extracted the estimate and 95% confidence interval for the association result. The ORs in retrospective studies were converted to RRs for meta-analysis (RR = OR/(\[1 − pRef\] + \[pRef \* OR\]), where pRef is the prevalence of CVD in the control group[@b30]. We then performed a non-parametric sign test of the extracted estimates with a null hypothesis of "no additional increased risk of CVD in OA patients"; we considered whether studies reported a higher or lower CVD risk associated with OA, regardless of significance level or magnitude of effect.

We calculated a pooled RR estimate across all studies using a random-effects model that assumes that individual studies estimate different association effects. The random-effects model was adopted because it is probably the most conservative analysis to account for variance within and between studies.

The between-study heterogeneity was assessed by means of the *I*^2^ statistic, calculated from the Q statistic[@b31]. We considered the result for heterogeneity significant at P \< 0.10 (two-sided) for the Q statistic. *I*^2^ \> 75% was considered a high level of heterogeneity.

Publication bias was assessed by visually examining the asymmetry of a funnel plot in which the log estimates were plotted against their standard errors. Furthermore, we also employed an Egger regression test in our analysis to calculate two-tailed P values for quantifying publication bias[@b32]. To test the robustness of our findings, we performed a multiple-step sensitivity analysis by important study quality components and by omitting each estimate one at a time.

To explore the influence of potential sources of heterogeneity on the pooled estimate, we carried out subgroup analyses by important study characteristics, including study design (prospective or retrospective), OA sites (hand, knee or hip), OA types (radiographic or clinical), and outcomes (ischemic heart disease, stroke, congestive heart failure, or cardiovascular death). The impact of mean age and follow up time on the pooled result was explored by meta-regression. Analyses were performed with Stata Version 12.0 (StataCorp LP, College Station, TX).
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###### Characteristics of the included studies.

  Study                           Design             Country                                Cohort                            CVD confirmation  Adjustment
  -------------------------- ----------------- ------------------- --------------------------------------------------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kadam *et al*.[@b9]          case-control     England and Wales          Morbidity Statistics in General Practice            medical record   Age, sex, social class, and number of other broad disease groups for which subjects consulted
  Nielen *et al*.[@b12]       cross-sectional      Netherlands      The Netherlands Information Network of General Practice    medical record   Age, gender, hypertension and hypercholesterolemia
  Jonsson *et al*.[@b4]        case-control          Iceland                         AGES Reykjavik study                         question      Age, smoking, cholesterol, triglycerides, body mass index, pulse pressure and statin use
  Ong *et al*.[@b14]          cross-sectional         U.S.                             NHANES 1999--2008                          question      Age, gender, race/ethnicity, and survey period
  Haara *et al*.[@b8]             cohort             Finland                                                                   medical record   Age, education, history of workload, smoking, and body mass index
  Kishimoto *et al*.[@b10]        cohort              U.S.                        The Honolulu Heart Program                   medical record   Age, BMI, physical activity index, hypertension, diabetes mellitus, HDL cholesterol, total cholesterol, smoking status, fibrinogen, alcohol intake, and ASA and/or NSAID use
  Hoeven *et al*.[@b6]            cohort           Netherlands                        The Rotterdam Study                      medical record   Age, sex, body mass index, diabetes, hypertension, total cholesterol/HDL cholesterol ratio and smoking
  Tsuboi *et al*.[@b17]           cohort              Japan                                                                    medical record   Age, gender, BMI, and lifestyle (smoking, drinking, and exercise habits)
  Barbour *et al*.[@b7]           cohort              U.S.                      Study of Osteoporotic Fractures                medical record   Age, body mass index, education, smoking, health status, diabetes, and stroke
  Haugen *et al*.[@b5]            cohort              U.S.                        The Framingham Heart Study                   medical record   Age, sex, cohort, BMI, total cholesterol: HDL ratio, current lipid-lowering treatment, increased blood pressure, current antihypertensive treatment, elevated fasting or non-fasting blood glucose, current antidiabetic treatment (oral or insulin), current use of NSAIDs, daily use of aspirin, current/previous smoking, alcohol use
  Kluzek *et al*.[@b11]           cohort               UK                             The Chingford study                      medical record   Age, smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication, occupation, BMI, HRT use, past physical activity, current/previous CVD disease, non-ASA NSAIDs and glucose levels
  Rahman *et al*.[@b16]       cross-sectional        Canada                          Medical Services Plan                     medical record   Age, sex, income, education, body mass index, physical activity, smoking, fruit and vegetable consumption, pain medication use, chronic obstructive pulmonary disease, hypertension and diabetes
  Nuesch *et al*.[@b13]           cohort             England                The Somerset and Avon Survey of Health             medical record   No adjustment
  Rahman *et al*.[@b15]           cohort            Canadian                   Canadian Community Health Survey                medical record   Age, sex, family history, high cholesterol, high blood pressure, diabetes mellitus, high body mass index (BMI), smoking, and diet
  Veronese *et al*.[@b18]         cohort              Italy                         Progetto Veneto Anziani                    medical record   Age; gender; waste-to-hip ratio; education level; presence at baseline of diabetes, hypertension, atrial fibrillation, chronic obstructive pulmonary disease; use at baseline of aspirin, anti-hypertensives, NSAIDSs; number of medications; smoking status; activities of daily living, mini-mental state, geriatric depression scale scores; glycosylated hemoglobin, total cholesterol, serum uric acid, estimated glomerular filtration rate, erythrocytes sedimentation rate; ankle brachial index; short physical performance battery and handgrip strength

###### Results for subgroup analyses.

  Subgroup                                             Included study                                 OA patients   CVD patients   Total participants        RR (95% CI)             P
  ---------------------- --------------------------------------------------------------------------- ------------- -------------- -------------------- ----------------------- -------------
  **Study design**                                                                                                                                                             
  Retrospective                             Refs [@b4],[@b9],[@b12],[@b14],[@b16]                       61,779         15,662           284,358           1.15 (0.95--1.38)        0.147
  Prospective             Refs [@b5], [@b6], [@b7], [@b8],[@b10],[@b11],[@b13],[@b15],[@b17],[@b18]     19,132         13,551            74,586         **1.30 (1.16--1.46)**   **\<0.001**
  **OA site**                                                                                                                                                                  
  Hand                                      Refs [@b4],[@b6],[@b8],[@b11],[@b18]                         6,587         3,256             15,728           1.03 (0.85--1.25)        0.749
  Knee                                         Refs [@b6],[@b11],[@b17],[@b18]                           1,593         2,106             7,796          **1.30 (1.00--1.69)**    **0.047**
  Hip                                              Refs [@b6],[@b7],[@b18]                               1,374         3,956             13,968         **1.23 (1.11--1.38)**   **\<0.001**
  **OA confirmation**                                                                                                                                                          
  Radiographic                   Refs [@b4], [@b5], [@b6], [@b7], [@b8],[@b11],[@b13],[@b17]             8,321         5,116             25,362         **1.23 (1.02--1.48)**    **0.028**
  Clinical                                         Refs [@b5],[@b6],[@b11]                                579          1,309             6,037            1.47 (0.91--2.39)        0.118
  **Outcome type**                                                                                                                                                             
  IHD                            Refs [@b4],[@b5],[@b9],[@b10],[@b14], [@b15], [@b16],[@b18]            71,207         8,480            177,253         **1.33 (1.20--1.46)**   **\<0.001**
  Stroke                               Refs [@b4],[@b5],[@b14], [@b15], [@b16],[@b18]                   59,429         3,469            151,321           1.11 (0.96--1.29)        0.16
  CHF                                       Refs [@b5],[@b9],[@b14],[@b15],[@b18]                       27,516         3,389             87,500         **1.40 (1.13--1.73)**    **0.002**
  Cardiovascular death                  Refs [@b7],[@b8],[@b11],[@b13],[@b17],[@b18]                     5,143         2,978             16,109         **1.53 (1.27--1.84)**   **\<0.001**
